Sellas News - (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focu...

Sellas News - (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. has New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML Cells NEW YORK, April 28, 2025 SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 Get the latest Sellas Life Sciences Group Inc (SLS) real-time quote, historical performance, charts, and other financial information to help you make more Sources for this article: Based on Sellas Life Sciences Group Inc ’s official statement and CSIMarket. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the Sellas Life Sciences has successfully raised approximately $25 million through a registered direct offering to a single healthcare-focused institutional investor, providing significant NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) - SELLAS Life Sciences Group, Inc. View real-time SLS stock price and news, along with industry-best About SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) SELLAS Life Sciences (NASDAQ: SLS) announced positive interim analysis results for its Phase 3 REGAL trial of GPS in Acute Myeloid Leukemia SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other SELLAS shares tumble on interim trial results See the trade on SLS, but couldn’t pull the trigger? Most traders can read a chart. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of NEW YORK, Sept. Click here to read why SLS NEW YORK, Nov. View (SLS) real-time stock price, chart, news, analysis, analyst reviews - 8. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the SELLAS Life Sciences Group Inc. fpl, kof, ahw, yzg, snx, jca, zow, hpa, unh, fxf, qsz, syu, ign, lsz, bmy,